Diagnostic HYBRIDS Hires HIV Virologist to Direct New Company Program.ATHENS, Ohio -- Diagnostic HYBRIDS announced today that Miguel E. Quinones-Mateu, Ph.D. has joined the company as director of its recently created HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. Program. His principal responsibility will be directing the technical and commercial development activities associated with novel assays for anti-retroviral drug resistance. "We are delighted that Dr. Quinones-Mateu has chosen to join DHI DHI see dairy herd improvement. . Miguel is a world class virologist virologist microbiologist specializing in virology. with an extraordinary track record in the field of HIV drug development and diagnostics," said David Scholl, Ph.D., president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Diagnostic HYBRIDS. "His molecular virology expertise will not only be used within our HIV Program but also with related molecular and cell-based projects in our pipeline. He will complement our strong scientific team nicely, and enable us to accelerate opportunity in the growing HIV drug resistance testing HIV drug resistance testing Phenotype testing AIDS The testing of various agents–eg, reverse transcriptase inhibitors, for efficacy against a particular strain of HIV Types Genotypic tests1, phenotypic test. Cf Genotype testing. market." Prior to joining Diagnostic HYBRIDS, Dr. Quinones-Mateu served as assistant professor in the Department of Molecular Genetics molecular genetics n. The branch of genetics that deals with hereditary transmission and variation on the molecular level. at the Lerner Research Institute of The Cleveland Clinic in Cleveland, Ohio. He has received several research grants throughout his academic tenure from the federal government (National Institutes of Health), private foundations, and industry. During his more than 16 years in the HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome field, his research efforts focused on HIV-1 genetic variability, evolution, fitness, and the relationship of these factors with drug resistance, including the study of novel antiviral strategies. "I am looking forward to this new challenge in my professional career. I am confident that the transition from academia to the corporate world will be greatly facilitated by the excellent technical staff at DHI. Moreover, I have no doubt that DHI's reputation and brand awareness for innovation and quality products within the clinical virology virology, study of viruses and their role in disease. Many viruses, such as animal RNA viruses and viruses that infect bacteria, or bacteriophages, have become useful laboratory tools in genetic studies and in work on the cellular metabolic control of gene expression community will translate well into the success of our novel HIV Program in both the diagnostic and clinical trial arenas," said Quinones-Mateu. Dr. Quinones-Mateu holds a bachelor's degree in biology from the Universidad Central de Venezuela where his initial work in HIV led to the first isolation and molecular characterization of HIV-1 isolates from Venezuela at the National Institute of Health in Caracas. He received his Ph.D. in Molecular Biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller from the Centro de Biologia Molecular "Severo Ochoa", Universidad Autonoma de Madrid (Spain), where he contributed to the first detection of drug-resistant viruses in patients never treated with antiretroviral drugs. Dr. Quinones-Mateu continued his training as a post-doctoral fellow in the Department of Medicine at Case Western Reserve University in Cleveland, Ohio. He focused his effort on the study of HIV-1 fitness and its relationship with drug resistance and disease progression, developing novel systems to quantify HIV-1 replicative fitness. Dr. Quinones-Mateu has authored numerous peer-reviewed publications, reviews and book chapters and has participated in multiple national and international grant review and advisory panels on AIDS and HIV Drug Resistance HIV drug resistance Antiretroviral drug resistance AIDS The resistance of a strain of HIV to an agent–eg, a reverse transcriptase inhibitor, which occurs in 5%-20% of those newly infected with HIV . About Diagnostic HYBRIDS Diagnostic HYBRIDS invents, develops, manufactures, and sells innovative diagnostic and analytical products for a wide range of viral respiratory diseases, herpes virus infections, and other specific viral and thyroid diseases. The company also develops and commercializes innovative and genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry, with an initial focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines. The company is certified to ISO (1) See ISO speed. (2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI. 13485 standards and manufactures live continuous and primary cell cultures for clinical diagnostics and pharmacology assays from its headquarters in Athens, OH. Diagnostic HYBRIDS was named one of the 500 Fastest Growing Companies in America in 2004 and 2005 by Inc. Magazine. The company is a pillar member of Omeris, a statewide organization of bioscience companies accelerating the bioscience and healthcare economy in Ohio. For more information, please visit www.dhiusa.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion